ESMO 2022 | Radiomics-based prediction of lymphocyte infiltration in IDH-wildtype glioblastoma

Maximilian Mair, MD, Medical University of Vienna, Vienna, Austria, provides an overview of an investigation into radiomics-based prediction of lymphocyte infiltration in isocitrate dehydrogenase (IDH)-wildtype glioblastoma. Response to immunotherapy has been demonstrated in a small yet undefined subgroup of patients with glioblastoma. Due to the lack of tissue availability and immunological diversity, identification of predictive biomarkers remains a challenge in this patient population. Previously, the volume of perifocal edema was shown to correlate with tumor-infiltrating lymphocyte (TIL) density in newly diagnosed IDH-wildtype glioblastoma. In the current study, a radiomic analysis demonstrated radiomic markers correlate with infiltration and density of PD-1-positive T-cells. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.